Search for other papers by Anne H van der Spek in
Google Scholar
PubMed
Search for other papers by Olga V Surovtseva in
Google Scholar
PubMed
Search for other papers by Saskia Aan in
Google Scholar
PubMed
Search for other papers by Anton T J Tool in
Google Scholar
PubMed
Search for other papers by Annemarie van de Geer in
Google Scholar
PubMed
Search for other papers by Korcan Demir in
Google Scholar
PubMed
Search for other papers by Anja L M van Gucht in
Google Scholar
PubMed
Search for other papers by A S Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Timo K van den Berg in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
Search for other papers by Anita Boelen in
Google Scholar
PubMed
potentially result in increased levels of IL-8. As elevated IL-8 was observed in patients both on and off levothyroxine, it appears to be an effect of the underlying condition, not its treatment. Intracellular TH metabolism is thought to play an important
Search for other papers by Florian W Kiefer in
Google Scholar
PubMed
found that TSH-suppressing treatment with levothyroxine (T4) induced BAT activity and browning of subcutaneous adipose tissue ( 56 ). The relevance of thyroid hormones for adipose browning in humans is also supported by findings that circulating free T4
Search for other papers by Marek Niedziela in
Google Scholar
PubMed
of patients; and the genetic cause of hyperthyroidism due to THRB mutation is rare and manifests in the foetal/neonatal period only in a very severe state. Iatrogenic hyperthyroidism is caused by an overdose of levothyroxine (LT4); goitre does
Search for other papers by Reem Al Argan in
Google Scholar
PubMed
Search for other papers by Abdulaziz Ramadhan in
Google Scholar
PubMed
Search for other papers by Ramanakumar V Agnihotram in
Google Scholar
PubMed
Search for other papers by Jeffrey Chankowsky in
Google Scholar
PubMed
Search for other papers by Juan Rivera in
Google Scholar
PubMed
assessment for secondary hypothyroidism should be reassessed. Clinical evaluation, along with measurement of free T4 and TSH, will dictate the need for levothyroxine replacement. Additionally, male patients, older patients, and patients whose tumors enhance
Search for other papers by Kinnaree Sorapipatcharoen in
Google Scholar
PubMed
Search for other papers by Thipwimol Tim-Aroon in
Google Scholar
PubMed
Search for other papers by Pat Mahachoklertwattana in
Google Scholar
PubMed
Search for other papers by Wasun Chantratita in
Google Scholar
PubMed
Search for other papers by Nareenart Iemwimangsa in
Google Scholar
PubMed
Search for other papers by Insee Sensorn in
Google Scholar
PubMed
Search for other papers by Bhakbhoom Panthan in
Google Scholar
PubMed
Search for other papers by Poramate Jiaranai in
Google Scholar
PubMed
Search for other papers by Saisuda Noojarern in
Google Scholar
PubMed
Search for other papers by Patcharin Khlairit in
Google Scholar
PubMed
Search for other papers by Sarunyu Pongratanakul in
Google Scholar
PubMed
Search for other papers by Chittiwat Suprasongsin in
Google Scholar
PubMed
Search for other papers by Manassawee Korwutthikulrangsri in
Google Scholar
PubMed
Search for other papers by Chutintorn Sriphrapradang in
Google Scholar
PubMed
Search for other papers by Preamrudee Poomthavorn in
Google Scholar
PubMed
as having undetermined cause. Patients with persistently high TSH after levothyroxine (LT 4 ) discontinuation after 3 years of age were diagnosed as having permanent CH. ‘Transient’ CH was diagnosed based on having normal thyroid function test results
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Marra Jai Aghajani in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Tara Laurine Roberts in
Google Scholar
PubMed
Saint Vincent’s Clinical School, UNSW Sydney, Sydney, Australia
SydPath, Saint Vincent’s Hospital, Sydney, Australia
Search for other papers by Tao Yang in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Search for other papers by Charles Eugenio McCafferty in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Centre for Oncology Education and Research Translation (CONCERT), Liverpool, New South Wales, Australia
Search for other papers by Nicole J Caixeiro in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
South West Sydney Clinical School, UNSW Sydney, Sydney, Australia
Search for other papers by Paul DeSouza in
Google Scholar
PubMed
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia
Department of Head & Neck Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia
Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
Search for other papers by Navin Niles in
Google Scholar
PubMed
patients typically involves surgical resection and suppression of thyroid-stimulating hormone (TSH) via levothyroxine, with additional consideration for adjuvant radioactive iodine (RAI) treatment to ablate residual thyroid tissue and eradicate any
Search for other papers by Nannan Bian in
Google Scholar
PubMed
Search for other papers by Xiaomeng Sun in
Google Scholar
PubMed
Search for other papers by Biao Zhou in
Google Scholar
PubMed
Search for other papers by Lin Zhang in
Google Scholar
PubMed
Search for other papers by Qiu Wang in
Google Scholar
PubMed
Search for other papers by Yu An in
Google Scholar
PubMed
Search for other papers by Xiaohui Li in
Google Scholar
PubMed
Search for other papers by Yinhui Li in
Google Scholar
PubMed
Search for other papers by Jia Liu in
Google Scholar
PubMed
Search for other papers by Hua Meng in
Google Scholar
PubMed
Search for other papers by Guang Wang in
Google Scholar
PubMed
disease, infectious disease, systemic inflammatory disease, mental illnesses, cancer or severe hereditary diseases were excluded. No subject took hypoglycemic drugs, antithyroid and levothyroxine drugs. We first divided the 287 participants into 3 groups
Department of Emergency Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland
Search for other papers by Lára Ósk Eggertsdóttir Claessen in
Google Scholar
PubMed
Search for other papers by Hafrún Kristjánsdóttir in
Google Scholar
PubMed
Department of Psychology, School of Social Sciences, Reykjavik University, Reykjavik, Iceland
Search for other papers by María Kristín Jónsdóttir in
Google Scholar
PubMed
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
Search for other papers by Sigrún Helga Lund in
Google Scholar
PubMed
Search for other papers by Ingunn Unnsteinsdóttir Kristensen in
Google Scholar
PubMed
Department of Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland
Search for other papers by Helga Ágústa Sigurjónsdóttir in
Google Scholar
PubMed
the 16 women with PD, thus 81% of women with PD needed medical treatment. All six women diagnosed with HP were started on treatment with HST (levothyroxine for central hypothyroidism n = 4, somatropin for GHD n = 2). Seven of the 10 women with HPRL
Search for other papers by Jakub Supronik in
Google Scholar
PubMed
Search for other papers by Małgorzata Szelachowska in
Google Scholar
PubMed
Clinical Research Centre, Medical University of Bialystok, Bialystok, Poland
Search for other papers by Adam Kretowski in
Google Scholar
PubMed
Search for other papers by Katarzyna Siewko in
Google Scholar
PubMed
mean duration of GO was 26 months (range 14–48), one patient was an active smoker , nine were ex-smokers and five never smoked. Five patients received AT combined with levothyroxine (LT), one patient received AT alone, and nine received LT alone. CAS